In thyroid tumors, RAS gene mutations can persistently activate the PI3K/AKT signaling pathway, thereby enhancing glycolytic flux and promoting the membrane localization of glucose transporter protein (GLUT1), which increases glucose uptake capacity. The gene discussed is SLC2A1; the disease is thyroid tumor.